Alfuzosin is a selective alpha-1 adrenergic receptor antagonist used primarily to treat benign prostatic hyperplasia (BPH). It works by relaxing the smooth muscles in the bladder neck and prostate, thereby improving urine flow and reducing symptoms of urinary obstruction. Unlike some other alpha-blockers, alfuzosin is uroselective, which reduces the risk of hypotension.
It is typically administered orally as an extended-release (ER) formulation.
Indications include:
∙ Benign prostatic hyperplasia (BPH)
∙ Off-label: Adjunct in managing urinary retention or bladder outlet obstruction
Parent: Alfuzosin
Parent: Alfuzosin
Parent: Alfuzosin/ Doxazosin/ Prazosin/ Terazosin
Parent: Alfuzosin
Parent: Alfuzosin
Parent: Alfuzosin
Parent: Alfuzosin
Parent: Alfuzosin
Parent: Alfuzosin
Parent: Alfuzosin / Alfuzosin Hydrochloride
Impurities in alfuzosin arise from its chemical synthesis, which involves formation of a quinazoline ring system, and from degradation under stress conditions such as heat, light, and pH changes. As it is used chronically in elderly patients, impurities must comply with ICH Q3A/B and USP/EP monograph limits.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Alfuzosin is used to treat benign prostatic hyperplasia (BPH) by relaxing the muscles of the bladder and prostate to improve urinary flow.
It blocks alpha-1 adrenergic receptors in the urinary tract, reducing smooth muscle tone in the bladder neck and prostate, thereby improving urine outflow.
While it has blood pressure–lowering effects, it is not approved for treating hypertension due to its uroselective action and potential for orthostatic hypotension.
Alfuzosin is generally stable but is sensitive to moisture and light. It should be stored in a cool, dry, and light-protected environment, especially in extended-release formulations.
